The Secret of Rocketship Education’s Success.

Rocketship Education prides itself on classroom management, technology use, and intervention. These key points were addressed at the National Charter School Association Conference in 2016 that was held in Nashville, TN. After the conference NPR, National Public Radio, depicted a rather severe picture of Rocketship Education. NPR questioned the schools use of discipline, culture, and boundaries. NPR also questioned what kind of technology is best for certain children and what technology may be harmful to certain children. This lead to questions about Rocketship’s Education staffing and teacher qualifications.

In most schools technology is the core of education. While NPR raises some good questions about Rocketship Education. It is better to look at the bigger picture and be aware of the responsibility society has regarding to children’s education. Schools should address the population on what steps are being taken to ensure each individual child is getting an excellent education.

Rocketship Education, is a non-profit charter school system. A charter school receives government funding but operates outside of the established state school system that the school is located within. The first Rocketship school opened in 2007 in San Jose, California. To date, Rocketship Education has 21 schools in the United States. Rocketship Education uses online and classroom teaching in conjunction with small group tutoring. This is called a hybrid model of individualized learning. This form of learning is highly successful in helping students from low-income families breach the achievement gap.

Since 2016, Rocketship Education has launched several new programs for its students. QueenHype is one such program, it empowers girls through communication in art and activism. The school offers a media literacy program which teaches children how to use media wisely. In 2018, students with an Individualized Educational Plan advanced a year and a quarter in math and reading.

While NPR raised some serious questions and was rather harsh when it concerned Rocketship Education. In 207 Rocketship Education addressed these questions within the system and changed it’s name to Rocketship Public Schools. As a result, enrollment has doubled and is expected to be on rise for the 2019-20 year.

Connect with Rocketship Education here

“Marc Beer – article recap “

Marc Beer is has contributed a lot to the health care industry. He is a founder, CEO, and Chairman; he has worked with various medical institutions and has brought development to such sectors. During the time he has functioned in the pharmaceutical industry he has made technological advancements, invented drugs, and create markets. Marc founded Renovia Inc. in August 2016 together with 2 of his partners; he successfully agreed with other health care firms. Marc Beer is also the CEO of ViaCell; he founded the firm in April 2000. The firm deals with all activities associated with the umbilical cord blood cells. Marc brought growth and profit to the organization making it an important commerce center. Through Marc’s management, the company grew tremendously and became publicized in 2005. PerkinElmer manages the company.


Marc Beer has had several executive positions over the years. He has also been among the board of directors of some pharmaceutical companies and has helped in coming up with important decisions and inventions. He operated as the Vice President of Global Marketing; his responsibilities were to announce the release of new drugs and treatment methods associated with uncommon diseases. Marc has played sales and marketing roles for health care firms selling pharmaceutical products. Marc Beer has also chaired various medical committees. Marc is an icon in the medical industry his contributions are globally appreciated. He has brought the medical industry to another level where therapeutic activities are carried out with technology.


Marc Beer is the founder of Renovia Inc. He is working together with other medical firms to come up with a diagnostic for pelvic floor disorder. The investment caused him a lot of funds, but he is dedicated to helping women overcome the disease. Renovia Inc. is based in Boston; the company is not only coming up with diagnostics but also treatment equipment and technology. According to medical experts, diseases affect a considerable percentage of women worldwide. Renovia has released the first product for the treatment of pelvic floor disorder which was approved by the FDA in April. The drug is known as Leva. Learn more:


The Longwood Fund joined the series B financing to help Renovia come up with solutions. The series B financing is led by Missouri-based Ascension Ventures and the New York Perspective Advisors. The firms will contribute funds for research, the invention of new diagnostics and upgrading the Leva product. Marc Beer is glad of the support he is getting from other health care firms. He is appreciative of the fact that they all share the same vision of helping women all over the globe. Marc Beer believes that through combining ideas and technology equipment, they will come up with the diagnostic within a short period.


Marc Beer, Renovia Inc’s Co-founder Expresses Gratitude For Receiving $42 Million Worth Of Funding

We are thrilled to have the support of this group of leading healthcare investors who share our vision to better diagnose, treat, and improve the lives of millions of women affected by pelvic floor disorders,” Marc Beer said in a recent press statement when acknowledging the $42 million funding. Two healthcare investors that have been adversely mentioned in the funding of what Renovia Inc calls Series B funding are Ascension Ventures, a Missouri-based healthcare company and Perceptive Advisors, a company whose base in New York.


The money that Renovia received is in two batches. The first batch is $32 million and the other $10 million is in the form of debt ventures. After receiving the money, Marc Beer announced that Renovia Inc will use it in developing and ensuring that its four products are ready for tests as soon as possible. Prior to Series B funding, Renovia received funding from Longwood Fund. During this initial funding, Renovia used the money to successfully launch Leva, the company’s debut product that was approved by FDA in April 2018. Since the FDA approval of the Leva product, Renovia has been working behind doors to present to the world other products. Beer said that the four products, together with an advanced generation of Leva will be out soon. Learn more:


During the acknowledgement statement, Beer added that the company will do everything it can to provide clients with the latest data. He added, “Combining our innovative and proprietary sensor technologies and form factors with a digital health platform will give our customers valuable data to inform new treatment options, drive greater knowledge, and understanding of pelvic floor disorders, and ultimately lower long-term healthcare costs.”


Marc Beer has more than 25 years of experience in the medical and biotechnology devices. He has worked for various healthcare service providers. One of the notable achievements under Marc’s belt is when he joined ViaCell. Marc joined this biotechnological firm in 2000. By the time he left, while presiding as the company’s Chief Executive Officer (CEO), the company had over 300 employees.


For more than 25 years, Marc Beer has been working for various healthcare providers. He has served in various capacities while in those companies. Marc has served in Global Marketing and Genzyme, among other companies. He ensures that he leaves a legacy whenever he gets out of a company. For instance, before leaving Global Marketing, he had risen to the position of the company’s VP. Other achievements include what he helped ViaCell achieve. Beer joined this biotechnological firm in 2000. When leaving this company a few years later, the startup had grown its employee list to over 300. Before leaving, Marc Beer participated in the company’s successful acquisition to PerkinElmer in 2007.